Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent, Refractory, or High Risk Leukemias”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT04160052
What this trial is testing

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+2 more
M.D. Anderson Cancer Center 51
Testing effectiveness (Phase 2)Ended earlyNCT03404193
What this trial is testing

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm+12 more
M.D. Anderson Cancer Center 235
Early research (Phase 1)Looking for participantsNCT05418088
What this trial is testing

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more
Sumithira Vasu 54
Testing effectiveness (Phase 2)Study completedNCT02921061
What this trial is testing

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Who this might be right for
Mixed Phenotype Acute LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid Leukemia+4 more
Fred Hutchinson Cancer Center 28
Testing effectiveness (Phase 2)Study completedNCT00027937
What this trial is testing

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Who this might be right for
LymphomaUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific
Fred Hutchinson Cancer Center
Not applicableStudy completedNCT00716911
What this trial is testing

Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
City of Hope Medical Center 100
Testing effectiveness (Phase 2)Study completedNCT00006265
What this trial is testing

Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Leukemia
Alliance for Clinical Trials in Oncology 60
Early research (Phase 1)WithdrawnNCT00521261
What this trial is testing

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Barbara Ann Karmanos Cancer Institute
Testing effectiveness (Phase 2)WithdrawnNCT05367401
What this trial is testing

Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Looking for participantsNCT04140487
What this trial is testing

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic/Myeloproliferative Neoplasm+3 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00002521
What this trial is testing

Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Temple University
Testing effectiveness (Phase 2)Study completedNCT02019069
What this trial is testing

CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
Adult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)+13 more
Rondeep Brar 11
Testing effectiveness (Phase 2)Looking for participantsNCT03670966
What this trial is testing

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in Remission+9 more
Fred Hutchinson Cancer Center 30
Early research (Phase 1)Study completedNCT01757639
What this trial is testing

Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome+3 more
National Cancer Institute (NCI) 42
Early research (Phase 1)Looking for participantsNCT03896269
What this trial is testing

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Who this might be right for
Blasts 10-19 Percent of Bone Marrow Nucleated CellsBlasts More Than 5 Percent of Bone Marrow Nucleated CellsHigh Risk Chronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 38
Early research (Phase 1)Study completedNCT01300572
What this trial is testing

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Who this might be right for
Chronic Myelomonocytic LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Lymphoblastic Leukemia+3 more
Fred Hutchinson Cancer Center 16
Early research (Phase 1)Study completedNCT00459212
What this trial is testing

GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia

Who this might be right for
Acute Undifferentiated LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)+13 more
National Cancer Institute (NCI) 24
Early research (Phase 1)Ended earlyNCT01408160
What this trial is testing

Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Adult B Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic Leukemia
Albert Einstein College of Medicine 18
Early research (Phase 1)Study completedNCT02484391
What this trial is testing

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Who this might be right for
Granulocytic SarcomaRecurrent Adult Acute Myeloid Leukemia
Wake Forest University Health Sciences 48
Early research (Phase 1)Study completedNCT00002588
What this trial is testing

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia

Who this might be right for
Leukemia
Case Comprehensive Cancer Center 30
Next Page
97